REMARKS

Applicant respectfully requests entrance of the amendments as detailed above in the above-referenced patent application.

Amendments to the Specification

The amendments to the specification, as detailed above, merely seek to incorporate information related to the U.S. patent application from which the present application is a Divisional and claims priority to. Applicant respectfully submits that no new matter is presented with these amendments.

Amendments to the Claims

Claims 1-23 have been canceled and new claims 24-42 have been added. Applicant respectfully submits that no new matter is presented with these amendments. Support for the new claims can be found in the claims as originally filed and throughout the specification. Specifically, claim 24 recites a method of using the chimeric peptides of the invention for the treatment of pain, whereby the chimeric peptides comprise an agonist opioid receptor binding moiety at its N-terminus and an agonist Substance P receptor binding moiety at its C-terminus. Support for such language can be found, for example, on page 17 lines 9-13 and Figures 1 and 2 in the teaching that working examples ESP6 and ESP7 were constructed so that the opioid receptor binding moiety (*e.g.*, endomorphin 2) is at the amino terminus and the SP receptor binding moiety is at the carboxy terminus of the chimeric peptide. With respect to the agonist nature of the opioid receptor binding moiety support can be found inter alia in Tables 1-3 and on page 13 line 11, page 14 line 3 and page 15 line 4 of the specification. In addition, with respect to the agonist nature of the SP receptor binding moiety, support can be found inter alia in the Examples and in Figure 9 in the teaching that testing for binding of the chimeric peptide ESP7 to SP receptors involved antagonizing the SP portion of the peptide with an appropriate antagonist (*e.g.* RP67580). See: page 23 lines 18-21 and page 25 lines 10-18 in the specification. One of ordinary skill in the art would appreciate that the SP receptor binding moiety of the chimeric peptides of the invention is thus understood to be agonist.

Claim 25 finds support *inter alia* in original claim 3 and, for example, in Tables 1-3 and on page 13 lines 11-18, page 14 lines 3-13 and page 15 lines 3-12 of the specification.

Claim 26 finds support, for example, in original claim 4, on page 13 lines 10-18 of the specification and in Table 1 on page 14 of the specification.

Support for claims 27-31 can be found inter alia in original claims 4 and 9, on page 13 lines 10-18 of the specification and in Table 1.

Support for claims 32-36 can be found in original claim 10, on page 16 lines 1-11 of the specification and in Table 4.

Claim 37 finds support *inter alia* in original claim 15.

Support for claims 38 and 39 can be found on page 17 lines 9-13 and in Figures 1 and 2.

Finally, claims 40-42 find support inter alia in original claims 21-23.

Applicant thanks the Examiner for his/her time and consideration. If a telephone conversation would help clarify any issues, or help expedite prosecution of this case, Applicant invites the Examiner to contact the undersigned at (617) 248-5150.

Although it is believed that there is no fee associated with this Amendment, if Applicant is mistaken, please charge any fees to our Deposit Account No.: 03-1721.

Respectfully submitted,
CHOATE, HALL & STEWART



Date: April 21, 2004

Nadège M. Lagneau, Ph.D.
Agent for Applicant
Reg. No.: 51,908

PATENT GROUP
CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, MA 02109
Tel: (617) 248-5150
Fax: (617) 248-4000